Results
71,174 records
Include
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | Altschuler RandolphDirector |  XMTRXometry, Inc.Open-market sale · 10b5-1 plan | SELL | $3,177 28 sh | Nov 6, 2026 |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | Altschuler RandolphDirector | XMTRXometry, Inc. Open-market sale · 10b5-1 plan | SELL | $3,177 28 sh | Nov 6, 2026 |
| 5 | Reske James REVP/Chief Financial Officer |  FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/Open-market sale · 10b5-1 plan | SELL | $2,196 100 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 5 |  Steinert LangleyDirector, Executive Chair, 10% Owner |  CARGCarGurus, Inc.Open-market sale · 10b5-1 plan | SELL | $8,378 224 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 5 | Steinert LangleyDirector, Executive Chair, 10% Owner | CARGCarGurus, Inc. Open-market sale · 10b5-1 plan | SELL | $22K 577 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 5 | Michaelson JenniferChief Scientific Officer |  CGEMCullinan Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $49K 4,000 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 5 | Reske James REVP/Chief Financial Officer | FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/ Open-market sale · 10b5-1 plan | SELL | $2,186 100 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 4 | Duffy Sean P.Director, Chief Executive Officer |  OMDAOmada Health, Inc.Open-market sale · 10b5-1 plan | SELL | $249K 12.9K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 4 | Brown Christopher D.Director |  MASS908 Devices Inc.Open-market sale · 10b5-1 plan | SELL | $329K 30.0K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 4 | King Ryan ADirector, Co-Founder |  CHYMChime Financial, Inc.Derivative conversion · 10b5-1 plan | C | — 63.4K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 4 | DelSanto AnneDirector |  AEISADVANCED ENERGY INDUSTRIES INCOpen-market sale · 10b5-1 plan | SELL | $53K 265 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 4 | Mehmel Robert FPresident and COO |  GFFGRIFFON CORPOpen-market sale · 10b5-1 plan | SELL | $89K 825 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 3 | Zerbe Robert L MdDirector |  VCELVericel CorpOption exercise · 10b5-1 plan | M | $33K 2,500 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 3 | Michaelson JenniferChief Scientific Officer | CGEMCullinan Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,805 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 3 | Rothblatt Martine ADirector, Chairperson & CEO |  UTHRUNITED THERAPEUTICS CorpOption exercise · 10b5-1 plan | M | — 9,500 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Malady KyleEVP and Group CEO-VZ Business |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,738 132 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Magliulo VirginiaExecutive VP |  ADPAUTOMATIC DATA PROCESSING INCOption exercise · 10b5-1 plan | M | $176K 852 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Peters William JDirector, CFO, EVP & TREASURER |  AMPHAmphastar Pharmaceuticals, Inc.Option exercise · 10b5-1 plan | M | $198K 11.0K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Leach BryanDirector, CEO AND PRESIDENT, 10% Owner |  IBTAIbotta, Inc.Derivative conversion | C | — 13.3K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Leach BryanDirector, CEO AND PRESIDENT, 10% Owner | IBTAIbotta, Inc. Derivative conversion | C | — 13.3K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Coyne Terrance P.EVP & CFO |  RPRXRoyalty Pharma plcGrant or award | A | — 7,122 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 10.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Pitofsky JasonSVP Controller |  REGNREGENERON PHARMACEUTICALS, INC.Option exercise | M | — 1,478 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Pitofsky JasonSVP Controller | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 905 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Urist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Grant or award | A | — 5,341 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Urist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Derivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 100.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Coxe TenchDirector |  NVDANVIDIA CORPGift · 10b5-1 plan | G | — 500.0K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 1 | O'Day Daniel PatrickDirector, Chairman & CEO |  GILDGILEAD SCIENCES, INC.Option exercise · 10b5-1 plan | M | $710K 9,810 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Hug JoshuaDirector |  RELYRemitly Global, Inc.Open-market sale · 10b5-1 plan | SELL | $122K 5,500 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Hug JoshuaDirector | RELYRemitly Global, Inc. Open-market sale · 10b5-1 plan | SELL | $118K 5,500 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | DIRK VAN DE PUTDirector, Chief Executive Officer |  MDLZMondelez International, Inc.Option exercise · 10b5-1 plan | M | $909K 20.9K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO |  ADPTAdaptive Biotechnologies CorpOpen-market sale · 10b5-1 plan | SELL | $147K 5,455 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $103K 4,000 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $155K 5,926 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $229K 8,400 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $210K 7,881 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $97K 3,481 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 0 | DIRK VAN DE PUTDirector, Chief Executive Officer | MDLZMondelez International, Inc. Option exercise · 10b5-1 plan | M | — 108.4K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | $144K 11.9K sh | Nov 6, 2026 traded Nov 6, 2026 |